Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Camp4 Therapeutics (CAMP) EBIT: 2023-2024

Historic EBIT for Camp4 Therapeutics (CAMP) over the last 2 years, with Dec 2024 value amounting to -$53.1 million.

  • Camp4 Therapeutics' EBIT fell 1.00% to -$13.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.8 million, marking a year-over-year decrease of 2.44%. This contributed to the annual value of -$53.1 million for FY2024, which is 2.33% down from last year.
  • Per Camp4 Therapeutics' latest filing, its EBIT stood at -$53.1 million for FY2024, which was down 2.33% from -$51.9 million recorded in FY2023.
  • Camp4 Therapeutics' EBIT's 5-year high stood at -$51.9 million during FY2023, with a 5-year trough of -$53.1 million in FY2024.
  • For the 2-year period, Camp4 Therapeutics' EBIT averaged around -$52.5 million, with its median value being -$52.5 million (2023).
  • Data for Camp4 Therapeutics' EBIT shows a maximum YoY fell of 2.33% (in 2024) over the last 5 years.
  • Camp4 Therapeutics' EBIT (Yearly) stood at -$51.9 million in 2023, then declined by 2.33% to -$53.1 million in 2024.